ANN ARBOR, Mich., March 28, 2011 /PRNewswire/ — Everist
Genomics today announced the worldwide commercial availability of
its OncoDefender-CRC colorectal cancer assay, the first and only
molecular prognostic test capable of accurately predicting the risk
of recurrence of cancer in patients previously treated with
surgical resection of a Stage I/II colon cancer tumor or Stage I
rectal cancer tumor. The OncoDefender-CRC test examines
expression levels of a panel of genes extracted from formalin-fixed
paraffin-embedded cancer tissue taken at the time of surgery, and
uses a proprietary computer-generated decision rule to identify
patients who are at risk of recurrence. Patients identified
by OncoDefender-CRC at high-risk of cancer recurrence may benefit
from adjuvant therapy or other more aggressive treatment options,
as reported at the 2011 American Society of Clinical Oncology
(ASCO) meeting. (1)
(Logo:
https://photos.prnewswire.com/prnh/20110110/NY26865LOGO)
“We are pleased to deliver a new molecular prognostic test
capable of assessing recurrence risk in early stage colorectal
cancer patients, including the neglected stage I subset, where the
lack of positive predictive prognostics presents a significant
unmet need,” said Prasad Sunkara, Ph.D., Chief Executive Officer of
Everist Genomics. OncoDefender-CRC was developed through
extensive clinical research and assay validation studies involving
over 500 patients from around the world. “OncoDefender-CRC
will help physicians make patient management decisions that
promptly and reliably direct the most effective treatment to those
individual Stage I/II colon cancer and Stage I rectal cancer
patients at high risk for tumor recurrence, while minimizing the
exposure of low-risk patients to unnecessary, costly, and
potentially toxic chemotherapy and/or radiotherapy.”
Traditional standards for assessing a patient’s risk of cancer
recurrence have depended solely on the cancer’s a
‘/>”/>
